GSK.NYSE

GlaxoSmithKline (GSK.NYSE) today announced positive headline results from five studies of the Phase 3 ASCEND program, evaluating the efficacy and safety profile of daprodustat, an investigational oral hypoxia-inducible factor…
GlaxoSmithKline (GSK.NYSE) today announced positive headline results from five studies of the Phase 3 ASCEND program, evaluating the efficacy and safety profile of daprodustat, an investigational oral hypoxia-inducible factor…